Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

facturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there is significant uncertainty regarding the level and timing of sales of ST-246 and when and whether it will be approved by the U.S. FDA and corresponding health agencies around the world. We cannot predict with certainty when SIGA will commence delivering any product or will begin recognizing profit on the sale thereof and there can be no assurance that any profits received by SIGA and paid to us will be significant. Furthermore, the Court of Chancery may grant SIGA's motion for reargument and the Court of Chancery decision could be appealed by SIGA, and there can be no assurances that the decision will not be reversed or that the remedy will not otherwise be modified. In addition, to the extent that there is an appeal, we cannot predict how long that will delay the receipt of payments, if any, from SIGA. Further, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for SparVax ™, Valortim® and our rBChE product. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com. -- Tables Follow --PHARMATHENE, INC.CONDENSED CONSOLIDATED BALANCE SHEETSSeptember 30,December 31,2011Unaudited2010ASSETSCurrent assets:Cash and cash equivalents$

10,406,076$

11,785,327Restricted cash100,000100,000Accounts receivable, net4,039,7015,367,130Other re
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... Physicists at the University of Pennsylvania have ... measuring the way it conducts electricity on a ... of graphene, the ultra-thin, single-atom thick carbon sheets ... silicon, the current material of choice for transistor ...
... SOUTH SAN FRANCISCO, Calif., July 31 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that the Company will ... Moores UCSD Cancer Center,Translational Oncology Symposium on Friday, ... Ph.D., director of preclinical and translational medicine,for Poniard ...
... HOUSTON and OTTAWA, July 31 /PRNewswire-FirstCall/ - iNutrition, ... Fission Fruit Bars, its,new all natural line of ... http://www.fissionbars.com, and come in three varieties; Fission ... Featuring morsels of,real, delicious fruits, Fission Bars have ...
Cached Biology Technology:Penn scientists demonstrate potential of graphene films as next-generation transistors 2Penn scientists demonstrate potential of graphene films as next-generation transistors 3Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium 2iNutrition Launches New Fission Fruit Nutrition Bars 2
(Date:4/23/2014)... RICHLAND, Wash. -- Like a hungry diner ripping open ... hydrogen into electricity must tear open a hydrogen molecule. ... catalyst holding onto the two halves of its hydrogen ... into how to make the catalyst work better for ... time scientists have shown precisely where the hydrogen halves ...
(Date:4/23/2014)... French and Spanish . ... CEC released its Conservation Assessment for the Big Bend-Ro ... identifies 29 priority conservation areas in a region straddling ... areas in the states of Texas, Coahuila, and Chihuahua. ... habitats inhabited by rare and endangered plants and animals, ...
(Date:4/23/2014)... (Apr. 23 2014) A team of ... cells (hNSCs) into the brains of nonhuman primates ... and 24 months found that the hNSCs had ... not cause tumors. , The study will be ... Transplantation but is currently freely available on-line ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... resistance of potatoes to late blight, their most important ... by the Biotechnology and Biological Sciences Research Council and ... Transactions of the Royal Society B , on 17 ... trial, the potatoes experienced ideal conditions for late blight. ...
... dividing to maintain our body functions. At each division, our ... to be faithfully duplicated to maintain the cell,s memory of ... developed a new technology that has revealed the dynamic events ... The results are published in Nature Cell Biology . ...
... power of regenerative medicine now allows scientists to transform ... pancreas cells and even neurons. However, a method to ... life-saving therapieshas proven far more difficult. But now, scientists ... San Francisco (UCSF), have made an important breakthrough: they ...
Cached Biology News:GM spuds beat blight 2New technology detect cellular memory 2Scientists transform skin cells into functioning liver cells 2Scientists transform skin cells into functioning liver cells 3
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications)....
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... 11.25 6.40 in. Mfr ...
Biology Products: